drugset
drugset / Trial / NCT02693652

A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine

NCT02693652 ↗

Phase 1/2 Completed 53 enrolled CHA Vaccine Institute Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A single center, open labeled phase I/IIa study to evaluate safety, tolerability and efficacy of a therapeutic hepatitis B vaccine in oral antiviral drug-treated chronic hepatitis B virus carriers

Timeline

Start
2014-10-28
Primary completion
2017-08-22
Completion
2017-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject CVI-HBV-002 Vaccine 20 ug Intramuscular
Subject CVI-HBV-002 Vaccine 40 ug Intramuscular

Indications

chronic hepatitis B virus infection